Clinical trial · Observational
microRNAs Tool for Stratifying Stage II Colon Cancer
microRNAs Tool for Stratifying Stage II Colon Cancer:a Perspective Study of Adjuvant Chemotherapy
NCT02635087CI-TRIAL-00020378unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators discover the investigators' miRNA tool can be a useful tool to predict the patients with stage II colon who can benefit from chemotherapy.Then the investigators plan to make an observation study that may validation this tool.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colonic Neoplasms | Colon Neoplasm | ALIAS | 0.90 |
| Effects of Chemotherapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| miRNA tool | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- high risk group
- description
- the miRNA tool predict this group of patients as "high risk"
- interventionNames
- Device: miRNA tool
Primary outcomes (1)
- measure
- DFS
- timeFrame
- 3 years
Secondary outcomes (1)
- measure
- OS
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * The informed consent has been obtained from the patient. * With confirmed diagnosis of stage II colon cancer. * With moderate/good ECOG health rating (PS): 0-1 score. * The patient receive no anti-cancer treatment before primary surgery. * The patient receive radical operation for colon cancer with negative margin. Exclusion Criteria: * With severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction. * With bad compliance or contraindication to enrollment. * Pregnant woman or lactating woman. * With contraindication to receive adjuvant chemotherapy.
References
Publications (0)
Data not yet available
No reference posted for this study.